Table 3 Respondent rankings of criteria that should be applied to define research priorities on access to medicines *
Items (proposed criteria) | Colombia | Dominican Republic | El Salvador | Suriname | E-mail survey | Total | |
|---|---|---|---|---|---|---|---|
g | Relevance (magnitude of the problem; persistence of the problem; impact on health; urgency) | 1.5 | 1.8 | 0.6 | 0.9 | 2.0 | 6.7 |
b | Feasibility (capacity of the system to carry out the research; funding support; justification of the cost/investment; justification of time) | 0.8 | 1.0 | 0.8 | 0.7 | 0.7 | 4.1 |
i | Research utilization (adequacy and usefulness of the current knowledge base (avoiding duplication); applicability of the research outcome; availability of cost-effective interventions (access); operational effectiveness) | 1.0 | 0.3 | 0.5 | 1.1 | 1.0 | 3.9 |
f | Political will/acceptability/commitment | 0.5 | 1.1 | 0.9 | 0.8 | 0.5 | 3.8 |
c | Human rights issues; equity focus; ethical and moral issues | 0.7 | 1.3 | 0.9 | 0.3 | 0.6 | 3.7 |
h | Responsiveness to the National Health Policy or national goals | 0.7 | 0.8 | 0.4 | 0.8 | 1.0 | 3.6 |
a | Community concern/demand; environmental health and sociopolitical effects | 0.3 | 0.3 | 1.1 | 0.9 | 0.4 | 3.0 |
d | Impact on development; economic impact | 0.2 | 0.6 | 0.5 | 0.4 | 0.3 | 1.9 |
e | Partnership building; research capacity building | 0.3 | 0.2 | 0.0 | 0.1 | 0.4 | 1.0 |